Article Text

Download PDFPDF
A once yearly IV infusion of zoledronic acid prevented fractures in postmenopausal women with osteoporosis

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In postmenopausal women with osteoporosis, does a once yearly intravenous infusion of zoledronic acid reduce the incidence of fractures?

Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★★★★ Rheumatology ★★★★★★★ Endocrine ★★★★★★☆ Geriatrics ★★★★★★☆


Embedded ImageDesign:

randomised placebo controlled trial (Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly [HORIZON]).

Embedded ImageAllocation:

not concealed.*

Embedded ImageBlinding:

blinded (outcome assessors).*

Embedded ImageFollow-up period:

36 months.

Embedded ImageSetting:

clinics in 25 countries in Europe, North and Latin America, Australia, and Asia.

Embedded ImagePatients:

7765 postmenopausal women (mean age 73 y) with a bone mineral density T score ⩽2.5 at the femoral neck, with or without vertebral fractures, or with a T score ⩽1.5 and ⩾2 mild or 1 moderate vertebral fractures. Women were grouped as stratum 1 (n = 6113) if they were not taking …

View Full Text


  • * See glossary.

  • For correspondence: Dr D M Black, University of California, San Francisco, CA, USA. dblack{at}

  • Source of funding: Novartis Pharma.

Linked Articles

  • Glossary
    BMJ Publishing Group Ltd